While we wait for results...
Just some amateur food for thought...
Here is the abstract from last year’s AACR
https://www.pharmagap.com/downloads/AACR_Therapeutic.pdf
From the above Abstract, I am not sure if Formulation 2 is the “enhanced variant” (referred to in the December 21st PR https://pharmagap.com/news/pr/12-21-2011.html) but these were Non-Liposomal Versions. It’s hard to see but under the "Results" section for cell proliferation, Formula 2 looks very compelling. Under the "Conclusions" it says F2 is significantly more potent in inhibiting proliferation.
Put this in a Liposome
“Liposomal delivery systems are an accepted, proven, and commercially viable strategy for the formulation of pharmaceuticals for clinical use. These delivery systems are employed to improve tumour targeting, modulate the pharmacokinetics of the active agent and enhance its stability following administration. Therapeutic activity may be improved by modulating drug exposure and accumulation (controlled release) in the region where the target cells are located.
https://pharmagap.com/news/pr/09-12-2011.html
Increase the half-life…
"Peptide half-life has been increased from a range of 0.4 to 0.7 for unformulated peptides to approximately 8 hours using intravenous administration and to approximately 40 hours using intraperitoneal administration. Liposomal associated peptide was detectable up to 72 hours post administration indicating that peptide remains in circulation for extended periods of time"
https://pharmagap.com/news/pr/11-25-2011.html
Am very curious to see what enhanced variant in a liposomal formulation that was detected even 72 hours post administration will be?
Wishing everyone the best,
GLTA!